Unique Considerations When Managing Hypertension in the Transplant Patient.
For the select fortunate recipients of organ transplants, transplantation affords the rare opportunity for a new life. Given the scarcity of organs for transplantation, it is imperative that the health of transplant recipients be optimized in order to fully benefit from this gift of life. Unfortunately, hypertension is highly prevalent in the transplant population and it is considered a major cardiovascular risk factor contributing to mortality and morbidity in this population. In this chapter, we expound on the epidemiology, unique pathophysiology, evaluation, and management of hypertension as it pertains to the solid organ transplant recipient. In addition, a brief commentary is made on the subject of hypertension following living kidney donation, and practical aspects of management of hypertension in the solid organ recipient are summarized at the end of the chapter.
William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN, USA.
Donald
D
Mitema
William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN, USA. Schinstock.carrie@mayo.edu.
Carrie
C
Schinstock
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D019520:Living Donors; D009392:Nephrectomy / Q000009:adverse effects; D012307:Risk Factors; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D007166:Immunosuppressive Agents
Blood pressure in solid organ transplant recipients; Calcineurin inhibitors; Hypertension; Post-transplant hypertension